364,000 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Acuta Capital Partners LLC

Acuta Capital Partners LLC purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 364,000 shares of the company’s stock, valued at approximately $1,795,000. Acelyrin makes up about 1.5% of Acuta Capital Partners LLC’s portfolio, making the stock its 21st largest holding. Acuta Capital Partners LLC owned approximately 0.36% of Acelyrin at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SLRN. Russell Investments Group Ltd. bought a new stake in Acelyrin during the 1st quarter valued at $183,000. Vanguard Group Inc. grew its stake in shares of Acelyrin by 1.3% in the first quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock worth $42,103,000 after acquiring an additional 81,633 shares during the last quarter. American International Group Inc. increased its stake in Acelyrin by 117.3% during the 1st quarter. American International Group Inc. now owns 35,793 shares of the company’s stock valued at $242,000 after purchasing an additional 19,318 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Acelyrin during the first quarter valued at approximately $140,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Acelyrin in the first quarter worth $192,000. 87.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on SLRN shares. Piper Sandler cut their target price on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Wells Fargo & Company boosted their price target on shares of Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. HC Wainwright raised their target price on shares of Acelyrin from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Finally, Morgan Stanley cut their target price on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.50.

Acelyrin Price Performance

Acelyrin stock opened at $4.57 on Thursday. Acelyrin, Inc. has a 12 month low of $3.36 and a 12 month high of $8.89. The stock has a market capitalization of $458.51 million, a PE ratio of -1.86 and a beta of 1.98. The business has a 50 day simple moving average of $5.39 and a 200-day simple moving average of $5.03.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.